Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Senti - Given the attack on NWBO what are the chances they don’t PR submission?
I was focused on Dr. Stephen Brem possibly presenting not just TTF but what was intimated at the end of the Q&A session on May 10th’s presentation. I maybe looking for needles in the wrong haystacks. My apologies if this is nothing pertinent as I’m not in the medical field.
I noticed these additional presentations at SNO:
Independent Supported Sessions at SNO
27th Annual Meeting and Education Day of the Society for Neuro-Oncology
November 16 - 20, 2022
Date: Wednesday, November 16, 2022
Time: 8:00AM – 4:30PM
Therapeutic Development in NeuroOncology Symposium
Location: Ballroom C, Tampa Convention Center
Symposium Chairs: Michael Vogelbaum MD, PhD and Peter Forsyth MD – Moffitt Cancer Center, Tampa, Florida
Speakers: For a full list of all of the speakers, click here.
On the list of speakers is:
Timothy Cloughesy
Professor of Neurology and Molecular and Medical Pharmacology
UCLA Health
In addition Dr. Stephen Brem will be speaking as well:
Date: Thursday, November 17, 2022
Time: 5:30PM – 7:30PM
Setting Our Sights on Improved Outcomes in Glioblastoma: State-of-the-Art Care with Tumor Treating Fields and Other Innovative Approaches
Location: Ballroom D, Tampa Convention Center
Speakers:
Steven Brem, MD - Penn Brain Tumor Center, Philadelphia, Pennsylvania
Manmeet Ahluwalia, MD, MBA - Miami Cancer Institute, Miami, Florida
Suriya Jeyapalan, MD, MPH - Tufts Medical Center, Boston, Massachusetts
Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities in sequential combination strategies across glioblastoma treatment settings.
In a new “Seminars & Practicum” event, expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature patient perspectives,
Looking forward to DCVax being available to those suffering from cancer.
Margaret
Survivor,
I have clubs and am planning to learn now that I am retired. The problem I see is that I’m living in Portugal and the commute to the states for a regular game of golf will be a challenge. Lol
Margaret
I play a mean putt putt golf. I’ve even gotten a hole in one a few times. I’ll be your 4th if you can’t find one of the boyz. Lol
So your park bench has a helical scan device. Impressive!
Thanks pgsd!
I’ve been pondering BO versus partnership of NWBO. I recall watching a video awhile back of Dr Linda Liau discussing how NWBO would be successful in the BP world. She talked about multiple partnerships with BP. That DCVAX would increase the revenue and effectiveness of BP’s products. I can’t find the video so I apologize for not posting the video referenced. If anyone has the video link I think it would be helpful to review earlier commentaries about how to navigate commercialization.
Good luck to patients, NWBO and all who support the company and believe in the science behind the DCVAX platform.
Margaret
Thanks Pgsd for restating the obvious for those who obviously don’t care that DCVAX works!
Good luck to patients, NWBO and investors who believe in the scientific facts about the DCVAX platform.
GLTU!
Margaret
Thanks Judge for your TA. Time to load up on more shares!
Prayers for patients, NWBO, and long time investors.
GLTU!
Margaret
Linda was seen at the NYAS presentation.
For those who have followed other biotech firms to commercialization, is MHRA acceptance of the MAA a material event?
Good luck to patients, NWBO and long term investors.
Margaret
Whose OS is no good? NWBO’s OS results are spectacular and DCVax outperformed the current SOC. If you’re discussing other companies, their results have nothing to do with NWBO. The exceptions would be any company that is involved in combination trials with NWBO. PFS is not an accurate reflection of results, OS is the MOST important indicator of success. We are fortunate that NWBO’s phase 3 trial continued long enough to verify it’s OS success in treatment of nGBM and rGBM with no side affects.
Good luck to patients, NWBO, and the investors who believe in the science and success of the DCVAX platform.
Margaret
Or 3) misheard what was said while reading the cc
Have some manners please.
Margaret
Flex - I was fooled too. Slowing the video down to 75% and not looking at the CC, I’ve changed my mind. I heard the word published not partnership.
According to YouTube there is no captioning. Where is the CC for this of us with hearing issues?
NVM I found it!!! Sigh…computer challenged.
I heard Dr. Ashkan say: “ straight (off) the press. Paper has
been submitted keeping (our) fingers crossed for
the reviewers and hopefully this new
partnership.” () edited from closed captioning
We don’t know which partnership he’s referring to however. Is it the publisher or other party? That’s the question I have. I hope it’s more than just a journal article! GL to patients, NWBO and all long time investors.
TDD Thanks for summarizing where we’ve been and where we’re headed! Good luck to patients and those that support them.
Margaret
Thanks pgsd!
TDD Thanks for the reminders of all NWBO has accomplished! Magrit
DL7 -Thanks for sharing your mother’s story. Sorry for your loss and her not being able to continue DCVax treatments. Hopefully soon access will be provided thru regulatory approval for the current GBM patient population.
pgsd I agree with you, the moonshot program in my opinion will help move approval along more expediently in the US than if this cancer initiative had not been created. Btw I’m living in Portugal now. Maybe someday when the dust settles from the move and I’m over in the UK we can meet for coffee and compare therapy modalities that we used in our practices. Sincerely, thank you for your continued contributions to this board. Obrigada!!! Margaret
Poor Man, I believe when you are settling into your park bench for an afternoon nap, your wife is out on the back nine practicing with your nine iron. Learn how to move like Neo please. Please practice for all of our sakes. We are invested in your well being here and I personally always root for the underdog to survive. Kinda like NWBO…exciting to cheer the company going from surviving to thriving.
Take care of you,
Margaret
NOTBOB17 Thank you for sharing. I’m a 10 year breast cancer survivor myself. Also, GBM took the life of a very wonderful member of my TaeKwon Do family. Our Sabum was a wonderful man, a positive force for good in the world…gone because of rGBM.
It’s different when it’s personal.
GLTA,
Margaret
What a huge relief! I wonder what the total number of long time investors here are cancer survivors? We all came to our NWBO investment from different pathways but I would bet that all of us have been impacted by cancer in one way or another. Some of us are here for more personal reasons than just an investment. I believe that is a big part of why the long term investors on this IHub BB are SO committed to seeing this treatment through to commercialization. Blessings of continued good health to you reg2015 and to all.
Take care,
Margaret
Best burn I’ve seen on here! GLTU Viking. Obviously I still respect you enough to read and respond to your posts!
Take care,
Margaret
Thanks BBB for setting the zoom call up for the group, your expertise and contribution to NWBO stockholders is much appreciated.
Dr Cloughesy presents at ASCO about GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.
https://meetings.asco.org/abstracts-presentations/search?query=*&q=cloughesy&sortBy=Relevancy&filters=%7B%22meetingTypeName%22:%5B%7B%22key%22:%22ASCO%20Annual%20Meeting%22%7D%5D,%22meetingYear%22:%5B%7B%22key%22:2022%7D%5D,%22presentationType%22:%5B%7B%22key%22:%22Abstract%20Presentation%22%7D,%7B%22key%22:%22Poster%22%7D,%7B%22key%22:%22Abstract%22%7D%5D%7D&size=50&cmpid=ws_ascoorg_am_abstracts_sno_twitter_all_042722____aware_image-text_
***Sorry old article*** Has this already been reported? Article by Drug Development and Treatment:
Northwest Biotherapeutics Aims to Dominate Brain Cancer
Interesting paragraph at the end of the article:
“Dr. Vivek Subbiah, an Oncologist at MD Anderson Cancer Center in Houston who is leading the DCVax-Direct trials, said he may present initial data at the annual meeting of the American Society of Clinical Oncology that begins May 30. Subbiah and his colleagues test scores of experimental cancer drugs, many having new mechanisms of action.”
https://drug-dev.com/northwest-biotherapeutics-aims-to-dominate-brain-cancer/
Just sent this tweet:
I read your article about the devastating brain cancer of the Phillies players. An idea for an inspirational story about GBM. First significant progress made in GBM treatment in decades. Please check out DCVax-L and the presentation at NYAS on 5/10/22. @joshuaqnelson #NWBO #DCVax
Thank you. Blocking me doesn’t deter from the fact that all of the commentators are criticizing his tweet on twitter. No matter how much he tries to block the truth, the scientific truth will be what endures after his sophomoric attempts at stock price manipulation.
GLTA patients
Margaret
My one goal for the day is done!!! Adam has blocked me too and that just made my day! I can stop adulting for the rest of the day now…lol
I’ve been blocked! Yes!!! $NWBO #DC-VAC pic.twitter.com/OeHAYOvhpH
— Margaret Monson (@MargaretMonson3) May 18, 2022
If there’s a trap set for stock manipulators (and this is TOTAL conjecture by me), I believe NWBO’s management has set it up beautifully. It’s a way of getting the stock manipulators to expose themselves flagrantly without the company saying anything. The company can’t legitimately due to their agreement with the journal. Who benefits long term by their behavior? NWBO does. The truth will prevail, they’ll stick to their rollout plan and not reactively to morally corrupt individuals. Which if they did, could potentially be playing into the hands of the criminals. No one can infer the company tried to pump their product prior to data publication and rollout. The will advertise based on solid science and a peer reviewed journal publication.
Margaret
Give me a list and I will write an email, text message, or tweet them about NWBO. Better yet, let’s both write them. One down and how many to go? Probably not that many as more information is provided in the next 6 weeks. We’ll (imo) see the narrative change to the successful trial by Dr. Liau, et. al. NWBO will be touted in the biotech industry as the David in the David and the Goliath story. That as a company they are successfully navigating in a very tough environment. Hopefully they will all receive the recognition and respect due all of them for their dedication to a cancer cure and determination to bring this treatment to the world under intense and corrupt criticisms. (There are legitimate constructive criticisms too of NWBO, I’m not speaking to those in this context).
Margaret
I cannot locate it but others indicate it is still there. AACR needs to publish a retraction not just bury their published material.
I want to be blocked!
Just sent this to AF:
You’re wrong the science is correct. DC-Vax L does better in OVERALL SURVIVAL than the current standard of care and will be approved for GBM patients. $NWBO
Your wrong the science is correct. DC-Vax L does better in OVERALL SURVIVAL than the current standard of care and will be approved for GBM patients. $NWBO
— Margaret Monson (@MargaretMonson3) May 18, 2022
Count me in!
D-Vax L will be approved as new SOC (imo) the science backs this by statistically showing that it improve overall survival over that which is standard care currently.
Here’s my current theme song:
Living In The Moment by Jason Mraz
https://pandora.app.link/YK4dgPL74pb
ASCO this year is going to be a blast! NWBO has a proven effective treatment for nGBM and rGBM that is better than what is being used currently. According to the DC-Vax L presentation on May 10th there has not been any progress in treating GBM for quite awhile. Specifically there hasn’t been any progress on nGBM treatments for 17 years and rGBM in 27 years. Cannot wait to see what the next 6 1/2 weeks unfolds.
Margaret
Remember when we were excited about ASCO approaching?
Unless selling the current stock price doesn’t matter and is not a reflection of the trial results. The science is effective. DC-Vax L is statistically more effective than the current standard of care in overall survival of GBM. This will be FDA’s new SOC (imo) and the stock price will rebound as people find out the truth of the science.
Margaret